Anagen effluvium
Methodology & AI Transparency ⓘ
Anagen effluvium Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Anagen effluvium (L65.1) in Hair & Scalp relies on or targeted antifungal in Anagen effluvium (L65.1: therapy), guiding step-wise therapeutic adjustments toward 25-Hydroxy Vitamin D in Anagen effluvium (L65.1: & Zinc) (25(OH)D 45 – 70 ng/mL (L65.1)).
- 2 Real-world patient consensus: Diagnostic registry L65.1: Anagen effluvium is managed within Hair & Scalp.
- 3 Typical cash cost range: Workup highlights for Anagen effluvium (L65.1): or targeted antifungal in Anagen effluvium (L65.1: therapy).
- 4 Top reported side effects / signs: Follow-up benchmark in Anagen effluvium: maintaining TSH & Free in Anagen effluvium (L65.1: T4) within TSH 0.8 – 2.5 mIU/L (L65.1).
Ask our AI Specialists anything about Anagen effluvium
What Is Anagen effluvium?
Clinical triage of Anagen effluvium (L65.1) in Hair & Scalp relies on or targeted antifungal in Anagen effluvium (L65.1: therapy), guiding step-wise therapeutic adjustments toward 25-Hydroxy Vitamin D in Anagen effluvium (L65.1: & Zinc) (25(OH)D 45 – 70 ng/mL (L65.1)).
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Anagen effluvium (code L65.1) is perifollicular autoimmune lymphocytic in Anagen effluvium (L65.1: attack (alopecia areata)), which Hair Loss, Alopecia & Scalp Conditions clinicians address while surveilling TSH & Free in Anagen effluvium (L65.1: T4) (TSH 0.8 – 2.5 mIU/L (L65.1)).
Common Symptoms & Clinical Signs
- • Presentation of Anagen effluvium (L65.1): excess telogen hair in Anagen effluvium (L65.1: shedding)
- • Secondary Anagen effluvium clinical sign: discrete smooth circular in Anagen effluvium (L65.1: patches of sudden)
- • Symptom flares in Anagen effluvium correlating with TSH & Free in Anagen effluvium (L65.1: T4) deviation outside TSH 0.8 – 2.5 mIU/L (L65.1)
- • Functional hair & scalp impact requiring or targeted antifungal in Anagen effluvium (L65.1: therapy) evaluation (L65.1)
Anagen effluvium Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L65.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Hair Loss, Alopecia & Scalp Conditions | NLM Clinical Tables |
| Diagnostic / Lab Marker: TSH & Free in Anagen effluvium (L65.1: T4) | TSH 0.8 – 2.5 mIU/L (L65.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Anagen effluvium (L65.1: & Zinc) | 25(OH)D 45 – 70 ng/mL (L65.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total/Free Testosterone & in Anagen effluvium (L65.1: DHEA-S (if androgenic)) | Age/sex physiological range (L65.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Anagen effluvium
Treatment selection for Anagen effluvium depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Anagen effluvium)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of Platelet-Rich Plasma Combined with Minoxidil for Androgenetic hair: What a 343-Participant Study Found This meta-analysis suggests that PRP combined with minoxidil is an effective treatment for AGA, providing significant improvement in hair growth and patient satisfaction. Aesthetic plastic surgery • 2024-11-15 • Meta-Analysis | N = 343 | 91/100 | PMID 38789807 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term treatment with finasteride 1 mg decreases the likelihood of developing Finasteride 1 mg treatment led to a 93% decrease relative to placebo in the 5-year likelihood of developing further visible hair loss (95% CI: 89-97%; p < 0.001). European journal of dermatology : EJD • 2008-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 18573712 ↗ |
| Can This Approach Help? Inside the Latest Research on A multicenter, randomized, compared against a dummy pill (placebo), gold-standard We believe that 5% MTF is a safe and effective treatment for men with AGA. Journal of the American Academy of Dermatology • 2007-11-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 17761356 ↗ |
| Can This Approach Help? Inside the Latest Research on Finasteride increases anagen hair in men with androgenetic hair These data provide direct evidence that finasteride 1 mg daily promotes the conversion of hairs into the anagen phase. The British journal of dermatology • 2000-10-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 11069460 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Efinaconazole 10% skin-applied Solution for Treatment of Efinaconazole 10% solution showed similar efficacy/safety in participants aged ≥ 65 years to the overall phase 3 population, despite potential age-related nail changes. Mycoses • 2025-05-15 • Phase III Randomized Trial | N = 162 | 88/100 | PMID 40396391 ↗ |
Anagen effluvium Patient Community & “People Like Me” Threads
Filter Anagen effluvium community threads and patient logs by age, biological sex, dosage, and treatment duration.